- Home
- MKTW vs SNTI Comparison
MKTW vs SNTI Comparison
Compare MKTW & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- SNTI
- Stock Information
- Founded
- MKTW 1999
- SNTI 2016
- Country
- MKTW United States
- SNTI United States
- Employees
- MKTW N/A
- SNTI N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MKTW Technology
- SNTI Health Care
- Exchange
- MKTW Nasdaq
- SNTI Nasdaq
- Market Cap
- MKTW 48.2M
- SNTI 39.6M
- IPO Year
- MKTW N/A
- SNTI N/A
- Fundamental
- Price
- MKTW $17.65
- SNTI $1.28
- Analyst Decision
- MKTW Hold
- SNTI Strong Buy
- Analyst Count
- MKTW 1
- SNTI 2
- Target Price
- MKTW $20.00
- SNTI $8.50
- AVG Volume (30 Days)
- MKTW 13.9K
- SNTI 136.3K
- Earning Date
- MKTW 11-06-2025
- SNTI 08-07-2025
- Dividend Yield
- MKTW 4.48%
- SNTI N/A
- EPS Growth
- MKTW 59.71
- SNTI N/A
- EPS
- MKTW 2.83
- SNTI N/A
- Revenue
- MKTW $358,121,000.00
- SNTI N/A
- Revenue This Year
- MKTW N/A
- SNTI N/A
- Revenue Next Year
- MKTW N/A
- SNTI $150.00
- P/E Ratio
- MKTW $6.30
- SNTI N/A
- Revenue Growth
- MKTW N/A
- SNTI N/A
- 52 Week Low
- MKTW $9.08
- SNTI $1.31
- 52 Week High
- MKTW $21.74
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- MKTW 43.71
- SNTI 24.65
- Support Level
- MKTW $17.70
- SNTI $1.38
- Resistance Level
- MKTW $18.08
- SNTI $1.47
- Average True Range (ATR)
- MKTW 0.40
- SNTI 0.09
- MACD
- MKTW -0.03
- SNTI -0.01
- Stochastic Oscillator
- MKTW 22.73
- SNTI 4.93
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.